Trial Profile
A Prospective, Randomised Study to Assess Safety, Changes in Platelet Reactivity, Plasma Cardiac Biomarkers, Immunological and Metabolic Parameters in HIV-1 Infected Subjects Undergoing a Switch in Antiretroviral Therapy.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary) ; Abacavir; Didanosine; Peptide hydrolase inhibitors
- Indications HIV-1 infections
- Focus Pharmacodynamics
- Acronyms SMASH
- 10 Sep 2019 Status changed from completed to discontinued.
- 20 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 31 May 2012 United Kingdom Clinical Research Network reports accrual to date changed from 42% to 45%.